Literature DB >> 14977834

Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome.

Antonio Marchetti1, Fabio Barassi, Carla Martella, Antonio Chella, Simona Salvatore, Antonio Castrataro, Felice Mucilli, Rocco Sacco, Fiamma Buttitta.   

Abstract

PURPOSE: The aim of this study was to evaluate the prevalence and the clinical significance of HIN-1 mRNA expression in early stage non-small cell lung carcinomas (NSCLCs). EXPERIMENTAL
DESIGN: A series of 91 NSCLC patients with stage I neoplastic disease was studied. HIN-1 expression was investigated by quantitative real-time reverse transcription-PCR on tumor specimens and matching normal lung tissues. Variables were analyzed by chi(2) test and Fisher's exact tests. Survival was evaluated with the method of Kaplan-Meier. Multivariate analysis was performed with Cox's proportional hazards model.
RESULTS: Seventy one (78%) tumors showed a reduction of HIN-1 mRNA compared with the normal counterpart. The range of reduction varied greatly, from -2-fold to -3350-fold. Setting a cutoff at -46-fold (median value of HIN-1 mRNA reduction), 46 cases (51%) had a markedly reduced expression, and 45 cases (49%) showed a normal or slightly reduced expression. A statistically significant association between low HIN-1 mRNA levels and T status was observed (P = 0.036). Univariate survival curves, estimated using the method of Kaplan-Meier, defined a significant association between HIN-1 expression and both overall survival (P = 0.0095) and disease-free survival (P = 0.0122). A multivariate analysis, performed by Cox's proportional hazards regression model, confirmed that a low HIN-1 expression was the only significant factor to predict poor prognosis.
CONCLUSIONS: Our data indicate that HIN-1 expression, measured by real-time reverse transcription-PCR, is a possible prognostic factor in patients with stage I NSCLC. Additional studies are required to further validate this potential prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14977834     DOI: 10.1158/1078-0432.ccr-1174-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq.

Authors:  Jennifer Beane; Jessica Vick; Frank Schembri; Christina Anderlind; Adam Gower; Joshua Campbell; Lingqi Luo; Xiao Hui Zhang; Ji Xiao; Yuriy O Alekseyev; Shenglong Wang; Shawn Levy; Pierre P Massion; Marc Lenburg; Avrum Spira
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis.

Authors:  Barbara Cecchinelli; Luca Lavra; Cinzia Rinaldo; Stefano Iacovelli; Aymone Gurtner; Alessandra Gasbarri; Alessandra Ulivieri; Fabrizio Del Prete; Maria Trovato; Giulia Piaggio; Armando Bartolazzi; Silvia Soddu; Salvatore Sciacchitano
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 3.  Novel insights into the molecular origins and treatment of lung cancer.

Authors:  James D Webb; M Celeste Simon
Journal:  Cell Cycle       Date:  2010-10-11       Impact factor: 4.534

4.  AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer.

Authors:  Yuanzi Yu; Dongtao Yin; Mohammad O Hoque; Baoping Cao; Yan Jia; Yunsheng Yang; Mingzhou Guo
Journal:  Tumour Biol       Date:  2011-11-19

5.  HIF-2alpha deletion promotes Kras-driven lung tumor development.

Authors:  Jolly Mazumdar; Michele M Hickey; Dhruv K Pant; Amy C Durham; Alejandro Sweet-Cordero; Anil Vachani; Tyler Jacks; Lewis A Chodosh; Joseph L Kissil; M Celeste Simon; Brian Keith
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-21       Impact factor: 11.205

Review 6.  Biomarkers of disease recurrence in stage I testicular germ cell tumours.

Authors:  Peter Lesko; Michal Chovanec; Michal Mego
Journal:  Nat Rev Urol       Date:  2022-08-26       Impact factor: 16.430

7.  HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme.

Authors:  M Herranz; M E Padín-Iruegas; Nieves Martínez-Lago; S Aguín Losada; P Raña-Díez; E Brozos Vázquez; J J Carrera; J R Antúnez; A Ruibal; R López-López
Journal:  Mol Neurobiol       Date:  2015-03-11       Impact factor: 5.590

8.  Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.

Authors:  Fabrizio Bianchi; Paolo Nuciforo; Manuela Vecchi; Loris Bernard; Laura Tizzoni; Antonio Marchetti; Fiamma Buttitta; Lara Felicioni; Francesco Nicassio; Pier Paolo Di Fiore
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

9.  Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.

Authors:  Chih-Ming Ho; Chi-Jung Huang; Chia-Yen Huang; Yih-Yiing Wu; Shwu-Fen Chang; Wen-Fang Cheng
Journal:  Mol Cancer       Date:  2012-08-08       Impact factor: 27.401

10.  Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.

Authors:  Eliana Bignotti; Renata A Tassi; Stefano Calza; Antonella Ravaggi; Elisa Rossi; Carla Donzelli; Paola Todeschini; Chiara Romani; Elisabetta Bandiera; Laura Zanotti; Mario Carnazza; Francesco Quadraro; Germana Tognon; Enrico Sartori; Sergio Pecorelli; Dana M Roque; Alessandro D Santin
Journal:  J Transl Med       Date:  2013-07-02       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.